Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts.
It is a $61.8B healthcare company. Revenue grew 13.5% over the last year, it keeps 17¢ of every dollar of sales as profit, and its net debt equals ~2.6 years of free cash flow. It trades at 16.9× earnings — near the lowest of its own history.
- Website
- bostonscientific.com
- Location
- Marlborough, MA
- Employees
- 59 000
- Sector
- Healthcare
- Founded
- 1965
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong valuation and quality; Moat lags behind.
Valuation85
- P/E vs own history1th pct · 25/25
- FCF yield5.9% · 20/25
- P/S2.9x · 20/25
- EV/EBITDA14.6x · 20/25
Growth65
- Revenue CAGR14.0% · 20/25
- Net income CAGR31.0% · 25/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growth28.4% · 20/25
Profitability64
- ROIC9.4% · 12/25
- ROE14.9% · 12/25
- Net margin17.5% · 20/25
- Operating margin19.8% · 20/25
Health67
- Altman Z2.58 · 18/25
- Current ratio1.24 · 12/25
- Interest coverage18.5x · 25/25
- Net cash / debtD/A 22% · 12/25
Quality84
- Piotroski F7/9 · 22/25
- Beneish M-2.42 · 20/25
- FCF conversion99% · 22/25
- Margin stabilityσ 6.0% · 20/25
Moat48
- ROIC >12% years0/10 yrs · 0/25
- Median gross margin69.3% · 25/25
- FCF-positive years9/10 yrs · 18/25
- Worst-year net marginworst -1.2% · 5/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- Q3 2026Insiders6 open-market insider purchases~197K shares bought by insiders
- FY2019FinancialRevenue crossed $10B$10.7B for the year
- FY2019FinancialPositive free cash flow every year since7-year streak
- FY2019FinancialBest year on record$4.70B net income
- FY2016FinancialFirst recorded profitable year$347M net income
- FY2016FinancialRevenue already above $1B$8.39B in first reported year
- 2016AcquisitionBoston Scientific acquired EndoChoice, located in Alpharetta, Georgia
- 2014AcquisitionBoston acquired hysteroscopic intrauterine tissue removal specialist, IoGyn, Inc
- 2011AcquisitionBoston acquired Atritech, Inc., for $100 million, plus up to $275 million in additional potential…
- 2010AcquisitionFour years later, in 2010, when moving its heart-rhythm business from its acquisition of Guidant, Boston Scientific…
- Apr 21, 2006AcquisitionBSC acquired Guidant for $27.2 billion
- 2005AcquisitionBSC exercised an exclusive option to acquire TriVascular, Inc., for an undisclosed sum and renamed it…
- 2004AcquisitionThe company announced that it had exercised an exclusive option to acquire Precision Vascular…
- Nov 3, 1998MilestoneBoston Scientific restated its financial results for 1997
- May 19, 1992IPOBoston Scientific launched an initial public offering of 23.5 million shares, of which 18.8 million…
- 1965FoundedLittle think tank in Cambridge, Massachusetts, and ran a contract research company from his rented house in Belmont,…
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (69.5%)
- Revenue growing 13.5% year over year
- Strong cash conversion — FCF is 17.3% of revenue
- Interest covered 18.5× by operating earnings
- Piotroski F-Score 7/9 — fundamentally strong checklist
Watch-outs
- Loss-making in 1 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+13.5% YoY
- Profitable — makes more than it spends$3.67B TTM
- Profit growing — earnings are higher than last year+58.7% YoY
- Generates cash — cash left after running and investing$3.63B TTM
- Debt under control — could handle its obligations~2.6y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$61.8B market cap
- Not printing shares — share count not ballooning — you keep your slice+5.5% shares over ~5y
- Proven track record — years of profitability behind it9/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 2.6 — grey
- Pays a dividend — returns cash to shareholdersnone
- Valuation not extreme — price not wildly above earningsP/E 16.9
Peer comparisonBoston Scientific Corp. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| BSX this company | $61.8B | 16.9 | +13.5% | 17.5% | Solid |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: BSX vs LLY · BSX vs JNJ · BSX vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/BSX
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of BSX on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $42.62 · market cap $61.8B.